Cancer research and therapy: Where are we today?
Till date scientists are struggling to understand the complete mechanism of carcinogenesis. In future, the real time detection of cancer may help scientists to identify some of the complicated biological mechanisms. Certain special features of cancer cells enable researchers to deliver the drug or to develop the right drug therapy. These cell properties include over expression or over activity in uptake of certain nutrients e.g. folic acid and increased permeability. Listed properties might vary depending upon the type of cancer and can be fully exploited by using nanoparticles either to detect the site of cancer or to direct the drug at the affected site. Product approach like drug conjugates, complexes serves as a good platform to solve issues like solubility, toxicity, poor penetration and stability related to cancer drugs. Beside this, several drug delivery platforms are under development by researchers in academia as well as in industry to deliver therapeutic molecules and new chemical entities to the targeted site in body. Amongst them, nanotechnology both at molecular and supramolecular level is a leading platform and can help to image, detect and treat cancer. Surface modification of nanoparticles by coating or anchoring their surface with special markers, materials, peptide, proteins, antibodies or antigens add extra feature and thereby can enhance the effectiveness. These treatments can be used individually or in combined form. In this review, advances on nanotechnological platform are discussed together with some assisting techniques like magnetic field, photo or light field, sonic rays are touched upon. New biological therapies that are advancing in this direction include the antisense therapy, cell therapy, gene therapy, radiation therapy and SiRNA interfaces which are discussed in brief in this article. This article gives short overview on use of complementary and alternative medicine for treatment of cancer such as traditional Chinese medicine (TCM), Ayurveda to avoid toxic effects of synthetic drugs.
IARC Press release, 2013. Available from http://ci5.iarc.fr/ [Accessed on May 02, 2014]
Stortecky S, Suter TM. Insights into cardiovascular side-effects of modern anticancer therapeutics. Curr Opin Oncol 2010; 22:312-7.
Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008; 58:97-110.
Aznar MA, Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int J Pharm 2013; 454:720-6.
Kang KW, Chun MK, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010; 6:210-3.
Narvekar M, Xue HY, Tran NT, et al. A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer. Eur J Pharm Biopharm 2014; 88:226-37.
Siddikuzzaman, Guruvayoorappan C, Berlin Grace VM. All trans retinoic acid and cancer. Immunopharmacol Immunotoxicol 2011; 33:241-9.
Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012; 7:49-60.
Jantscheff P, Ziroli V, Esser N, et al. Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clin Exp Metastasis 2009; 26:981-92.
Jantscheff P, Esser N, Graeser R, et al. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. Prostate 2009; 69:1151-63.
Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994; 125:642-9.
Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 1996; 37:351-5.
Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1:297-315.
P Farrell N. Platinum formulations as anticancer drugs clinical and pre-clinical studies. Curr Top Med Chem 2011; 11:2623-31.
Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 2004; 100:135-44.
Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006; 114:277-87.
Chiu GN, Abraham SA, Ickenstein LM, et al. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release 2005; 104:271-88.
Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J Drug Deliv 2011; 2011:591325.
Al-Ahmady ZS, Al-Jamal WT, Bossche JV, et al. Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo. ACS Nano 2012; 6:9335-46.
Lollo G, Rivera-Rodriguez GR, Bejaud J, et al. Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel. Eur J Pharm Biopharm 2014; 87:47-54.
Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008; 97:71-87.
Chen HM, Langer R. Oral particulate delivery: status and future trends. Adv Drug Del 1998; 34:339-50.
Kim GJ, Nie S. Targeted Cancer Nanotherapy. Materials Today 2005; 8:28-33.
Heinrich EL, Welty LA, Banner LR, Oppenheimer SB. Direct targeting of cancer cells: a multiparameter approach. Acta Histochem 2005; 107:335-44.
Wang C, Ho PC, Lim LY. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm 2010; 400:201-10.
Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005; 25:3825-31.
Tian X, Yin H, Zhang S, et al. Bufalin loaded biotinylated chitosan nanoparticles: an efficient drug delivery system for targeted chemotherapy against breast carcinoma. Eur J Pharm Biopharm 2014; 87:445-53.
Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Application of gold nanoparticles for targeted therapy in cancer. J Biomed Nanotechnol 2008; 4: 99-132.
Mukherjee P, Bhattacharya R, Patra CR, et al. Nanogold in Cancer Therapy and Diagnosis. Chapter 3, Wiley-VCH, Weinheim, Germany, 2007; 7.
Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010; 62:346-61.
Sathishkumar G, Gobinath C, Wilson A, Sivaramakrishnan S. Dendrophthoe falcata (L.f) Ettingsh (Neem mistletoe): a potent bioresource to fabricate silver nanoparticles for anticancer effect against human breast cancer cells (MCF-7). Spectrochim Acta A Mol Biomol Spectrosc 2014; 128:285-90.
Laha D, Pramanik A, Maity J, et al. Interplay between autophagy and apoptosis mediated by copper oxide nanoparticles in human breast cancer cells MCF7. Biochim Biophys Acta 2014; 1840:1-9.
Liu X, Tao H, Yang K, et al. Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials 2011; 32:144-51.
Liao MY, Lai PS, Yu HP, et al. Innovative ligand-assisted synthesis of NIR-activated iron oxide for cancer theranostics. Chem Commun (Camb) 2012; 48:5319-21.
Chu M, Shao Y, Peng J, et al. Near-infrared laser light mediated cancer therapy by photothermal effect of Fe3O4 magnetic nanoparticles. Biomaterials 2013; 34: 4078 –88.
Zhang X, Li F, Guo S, et al. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Biomaterials 2014; 35: 3650-65.
Peiris PM, Toy R, Abramowski A, et al. Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. J Contr Rel 2014; 173: 51-8.
Gabizon A, Goren D, Horowitz AT, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997; 24: 337-44.
Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005; 10: 205-14.
Shegokar R, Muller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010; 399: 129-39.
Yang HM, Oh BC, Kim JH, et al. Multifunctional poly(aspartic acid) nanoparticles containing iron oxide nanocrystals and doxorubicin for simultaneous cancer diagnosis and therapy. Colloids Surf A Physicochem Eng Asp 2011; 391:208-15.
Wang Y, Chen L, Tan L, et al. Biomaterials 2014, -Forthcoming in 2014. Available from
Casolaro M, Del Bello B, Maellaro E. Hydrogel containing L-valine residues as a platform for cisplatin chemotherapy. Colloids Surf B Biointerfaces 2011; 88:389-95.
Dörner L, Mustafa A, Rohr A, et al. Growth pattern of tumor recurrence following bischloroethylnitrosourea (BCNU) wafer implantation in malignant glioma. J Clin Neurosci 2013; 20: 429-34.
Dolatabadi J, Omidi Y, Losic D. Carbon nanotubes as an advanced drug and gene delivery nanosystem. Curr Nanosci 2011; 7:297-314.
Iijima S. Carbon nanotubes: past, present, and future. Phys B Condens Matter 2002; 323:1-5.
Journet C, Maser WK, Bernier P, et al. Large-scale production of single-walled carbon nanotubes by the electric-arc technique. Nature 1997; 388 :756-8.
Scott CD, Arepalli S, Nikolaev P, Smalley RE. Growth mechanisms for single-wall carbon nanotubes in a laser-ablation process. Appl Phys A Mater Sci Process 2001; 72:573-80.
Huang ZP, Wu JW, Ren ZF, et al. Growth of highly oriented carbon nanotubes by plasma-enhanced hot filament chemical vapour deposition. Appl Phys Lett 1998; 73:3845-7.
Seah CM, Chai SP, Mohamed AR. Synthesis of aligned carbon nanotubes. Carbon 2011; 49: 4613-35.
Ji Z, Lin G, Lu Q, et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Colloid Interface Sci 2012; 365:143-9.
Mehra NK, Verma AK, Mishra PR, Jain NK. The cancer targeting potential of D-a-tocopheryl polyethylene glycol 1000 succinate tethered multi walled carbon nanotubes. Biomaterials 2014; 35: 4573 -88.
Zhou S, Hashida Y, Kawakami S, et al. Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy. Int J Pharm 2014; 471:214-23.
Ruan J, Song H, Qian Q, et al. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer. Biomaterials 2012; 33: 7093-102.
Chu M, Pan X, Zhang D, et al. The therapeutic efficacy of CdTe and CdSe quantum dots for photothermal cancer therapy. Biomaterials 2012; 33: 7071- 83.
Vandamme M, Robert E, Dozias S, et al. Response of Human Glioma U87 Xenografted on Mice to Non Thermal Plasma Treatment. Plasma Med 2011; 1: 27-43.
Pietras A. Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011; 112:255-81.
Chen SY, Huang YC, Liu SP, Tsai FJ, Shyu WC, Lin SZ. An overview of concepts for cancer stem cells. Cell Transplant 2011; 20:113-20.
Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
Lauth M, Toftgard R. Hedgehog signaling and pancreatic tumor development. Adv Cancer Res 2011; 110:1-17.
Kelleher FC. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 2011; 32: 445-1.
Tanaka H, Nakamura M, Kameda C, et al. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24−/low subpopulation and the side population of breast cancer cells. Anticancer Res 2009; 29: 2147-57.
Feldmann G, Dhara S, Fendrich V, et al. Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67: 2187-96.
Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011; 141:2218-27.
Li W, Yuan Y, Huang L, et al. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012; 96:187-95.
Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007; 6:2967-75.
Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K. Radiosensitization by SAHA in Experimental Colorectal Carcinoma Models-In vivo Effects and Relevance of Histone Acetylation Status. Int J Radiat Oncol Biol Phys 2009; 74: 546-552.
Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9: 2582-92.
Zhang M, Ma Q, Hu H, et al. Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1alpha under normoxic condition. Cancer Lett. 2011; 303:108-17.
Tubiana M. The role of local treatment in the cure of cancer. Eur J Cancer 1992; 28A:2061-9.
Saha A, Chattopadhyay S. Assessment of pulmonary toxicities in breast cancer patients undergoing treatment with anthracycline and taxane based chemotherapy and radiotherapy- a prospective study. Int J Cancer Ther Oncol 2013; 1:01021.
Moorthy S, Sakr H, Hasan S, et al. Dosimetric study of SIB-IMRT versus SIB-3DCRT for breast cancer with breath-hold gated technique. Int J Cancer Ther Oncol 2013;1:010110.
Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353:267-72.
Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012; 24:112-24.
Ahmad SS, Duke S, Jena R, et al. Advances in radiotherapy. BMJ 2012; 345:e7765.
Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83-8.
Verellen D, De Ridder M, Linthout N, et al. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007; 7: 949-60.
Shang CY, Kasper ME, Kathriarachchi V, et al. Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery? Int J Cancer Ther Oncol 2014; 2:020317.
Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol) 2010; 22:157-72.
Rana S, Singh H. Impact of heterogeneities on lateral penumbra in uniform scanning proton therapy. Int J Cancer Ther Oncol 2013; 1:01026.
DeLaney TF. Proton therapy in the clinic. Front Radiat Ther Oncol 2011; 43:465-85.
Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Seminars in Cancer Biology 2012; 22: 23-32.
Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro F. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18: 23-34.
Melenhorst JJ, Barrett AJ. Tumor vaccines and beyond. Cytotherapy 2011; 13:8-18.
Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated irradiated allogeneic granulocytemacrophage colony stimulating factorsecreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of Surgery 2011; 253:328-335.
Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Nat Cancer Inst 2012; 104:599-613.
Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119-27.
Inogés S, de Cerio AL, Villanueva H, et al. Idiotype vaccines for lymphoma therapy. Expert Rev Vaccines 2011; 10:801- 9.
Silva J, Garcia V, Lopez-Gonzalez A, Provencio M. MicroRNAs as molecular markers in lung cancer. Int J Cancer Ther Oncol 2013; 1:010111.
Bommer GT, Gerin I, Feng Y, et al. p53- mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Bio 2007; 17:1298–307.
Shegokar R, Al Shaal L, Mishra PR. SiRNA delivery: challenges and role of carrier systems. Pharmazie 2011; 66:313-8.
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8.
Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526-34.
Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-61.
Parker KA, Glaysher S, Polak M, et al. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 2010; 63:1012-20.
Glaysher S, Gabriel FG, Cree IA. Measuring gene expression from cell cultures by quantitative reverse-transcriptase polymerase chain reaction. Methods Mol Biol 2011; 731:381-93.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.